Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H16O5 |
Molecular Weight | 324.3273 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)CC(C1=CC=CC=C1)C2=C(O)C3=C(OC2=O)C=C(O)C=C3
InChI
InChIKey=SKFYEJMLNMTTJA-UHFFFAOYSA-N
InChI=1S/C19H16O5/c1-11(20)9-15(12-5-3-2-4-6-12)17-18(22)14-8-7-13(21)10-16(14)24-19(17)23/h2-8,10,15,21-22H,9H2,1H3
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3397 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20429590 |
35.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20429590
Racemic 7-hydroxywarfarin inhibited recombinant CYP2C9 with IC50 35 uM.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID10939074
Created by
admin on Sat Dec 16 08:47:09 GMT 2023 , Edited by admin on Sat Dec 16 08:47:09 GMT 2023
|
PRIMARY | |||
|
17834-03-6
Created by
admin on Sat Dec 16 08:47:09 GMT 2023 , Edited by admin on Sat Dec 16 08:47:09 GMT 2023
|
PRIMARY | |||
|
B92SFW09LJ
Created by
admin on Sat Dec 16 08:47:09 GMT 2023 , Edited by admin on Sat Dec 16 08:47:09 GMT 2023
|
PRIMARY | |||
|
54682507
Created by
admin on Sat Dec 16 08:47:09 GMT 2023 , Edited by admin on Sat Dec 16 08:47:09 GMT 2023
|
PRIMARY |
PARENT (METABOLITE INACTIVE)
SUBSTANCE RECORD